Article
Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma.
Annals of clinical and laboratory science - 1 May 2022
Pero Stephanie C, Nagulapally Abhinav B, Mei Linda, Zhang Fan, Sholler Giselle S, Krag David N, Shukla Girja S
Abstract excerpt
OBJECTIVE: Tumor heterogeneity is a fundamental problem in treating cancer with monotargeting therapy, including chemical, antibody, and T cell therapies. Our goal is to target multiple mutated peptides found in a patient's cancer to increase antibody therapy effectiveness. METHODS: Tumor samples were derived from patients with neuroblastoma. Whole-exome sequencing was performed of tumor and normal cells. Mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.